Please assess the completion status of the following clinical trial:

Trial Title: Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* - Patients (≥18 years of age) admitted to the hospital with confirmed COVID-19 and not needing admission to MC or ICU~* Patient has moderate to severe COVID-19. This will be defined as patients with NEWS-2 score ≤ 5.~* Willing and able to give written informed consent~Exclusion Criteria:~* - Severe Covid-19 defined as NEWS-2 score \>5 or admission to the ICU needing ventilation or pressure support.~* Contra-indications for hydroxychloroquine or chloroquine~* Unable to take oral medication (chloroquine and hydroxychloroquine can be administered through tube feeding which is considered oral administration)~* Identified allergies to 4-aminoquinoline~* Severe diseases of the blood system~* 6-phosphate dehydrogenase deficiency~* History of acute myocardial infarction, unstable angina pectoris, severe arrhythmia (frequent ventricular, ventricular tachycardia, ventricular fibrillation) in recent 6 months; New York Heart Association (NYHA) level III-IV~* Known corrected QT interval (QTc) ≥ 500ms.~* Uncorrected severe hypokalaemia (\< 2,5 mmol/l) or uncorrected severe hypomagnesemia (\< 0.6 mmol/l)~* Pancreatitis~* Refusal to participate expressed by patient or legally authorized representative if they are present

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 110 Years
- Healthy Volunteers: t

Study Arms:
- chloroquine (Type: ACTIVE_COMPARATOR): 1. Supportive care + chloroquine base arm: loading dose 600mg, followed by 300mg 12 hours later, followed by 300mg bid for 4 days; total treatment duration of 5 days
- hydroxychloroquine (Type: ACTIVE_COMPARATOR): 2. Supportive care + hydroxychloroquine arm: loading dose 400mg bid, followed by 200mg bid for 4 days; total treatment duration of 5 days.
- Supportive care only (Type: NO_INTERVENTION): 3. Supportive care only.

Based on this trial design, predict the completion outcome and termination type (if applicable).